Fresenius SE Other Long-Term Assets 2016-2024 | FSNUY
Fresenius SE other long-term assets from 2016 to 2024. Other long-term assets can be defined as field containing the sum of all non-current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
- Fresenius SE other long-term assets for the quarter ending June 30, 2024 were $0.166B, a 93.91% decline year-over-year.
- Fresenius SE other long-term assets for 2023 were $0.543B, a 80.33% decline from 2022.
- Fresenius SE other long-term assets for 2022 were $2.761B, a 2.1% increase from 2021.
- Fresenius SE other long-term assets for 2021 were $2.705B, a 11.47% increase from 2020.
Fresenius SE Annual Other Long-Term Assets
(Millions of US $) |
| 2023 |
$543 |
| 2022 |
$2,761 |
| 2021 |
$2,705 |
| 2020 |
$2,426 |
| 2019 |
$2,275 |
| 2018 |
$2,276 |
| 2017 |
$2,004 |
| 2016 |
$1,776 |
| 2015 |
$1,642 |
Fresenius SE Quarterly Other Long-Term Assets
(Millions of US $) |
| 2024-06-30 |
$166 |
| 2024-03-31 |
$585 |
| 2023-12-31 |
$543 |
| 2023-09-30 |
$779 |
| 2023-06-30 |
$2,725 |
| 2023-03-31 |
$2,885 |
| 2022-12-31 |
$2,761 |
| 2022-09-30 |
$2,345 |
| 2022-06-30 |
$2,380 |
| 2022-03-31 |
$2,626 |
| 2021-12-31 |
$2,705 |
| 2021-09-30 |
$2,706 |
| 2021-06-30 |
$2,663 |
| 2021-03-31 |
$2,605 |
| 2020-12-31 |
$2,426 |
| 2020-09-30 |
$2,337 |
| 2020-06-30 |
$2,245 |
| 2020-03-31 |
$2,213 |
| 2019-12-31 |
$2,275 |
| 2019-09-30 |
$2,300 |
| 2019-06-30 |
$2,155 |
| 2019-03-31 |
$2,148 |
| 2018-12-31 |
$2,276 |
| 2018-09-30 |
$2,268 |
| 2018-06-30 |
$2,274 |
| 2018-03-31 |
$2,097 |
| 2017-12-31 |
$2,004 |
| 2017-09-30 |
$2,081 |
| 2017-06-30 |
$2,055 |
| 2017-03-31 |
$2,028 |
| 2016-12-31 |
$1,776 |
| 2016-09-30 |
$1,712 |
| 2016-06-30 |
$1,690 |
| 2016-03-31 |
$1,610 |
| 2015-12-31 |
$1,642 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Outpatient & Home Care |
$19.458B |
$24.011B |
|
Fresenius SE & Co is a health care company. It offers products and services for dialysis, hospitals and outpatient treatment. The company's business segment consists of Fresenius Medical Care is engaged in treating with chronic kidney failure; Fresenius Helios is a hospital operator; Fresenius Kabi supplies essential drugs, clinical nutrition products, medical devices and services and Fresenius Vamed plans, develops and manages healthcare facilities. Fresenius SE & Co is headquartered in Bad Homburg, Germany.
|
